IMR Press / EJGO / Volume 33 / Issue 2 / pii/1631086381202-475529020

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research
Prognostic importance of selected molecular immunohistochemical markers and DNA ploidy in endometrial cancer
Show Less
1 Department of Gynaecology and Obsterics, Faculty and University Hospital, Olomouc;
2 Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc
3 Institute of Pathology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc (Czech Republic)
Eur. J. Gynaecol. Oncol. 2012, 33(2), 159–163;
Published: 10 April 2012

The aim of the study was the analysis of the new molecular genetic immunomarkers (p53, c-erbB-2, Ki 67, bcl-2) hormonal receptors (ER, PR) and ploidy disturbances and their relation to the most important prognostic factors for endometrial cancer. The study group consisted of 135 endometrial cancer patients. Biopsies of the tumours obtained at operations were routinely histopathologically examined. Subsequenly, the immunohistochemical tumour markers were determined. The same biopsies were examined by microdissection and flow cytometric ploidy analysis and karyotyping. The findings were compared with the most important prognostic factors for endometrial cancer, mainly with clinical stage of the disease and grade. Results: High expression of p53, Ki 67, c-erbB-2 and low rate of progesterone receptors was found in the prognostically unfavourable group (G 3). Aneuploidy was found in 72% in the group of poorly differentiated endometrial cancers (G 3) in contrast to 27% in the group of G1 and G2 tumours, but this difference was not statistically significant. Conclusions: Identification of p53, Ki 67, c-erbB-2, PR and determination of DNA ploidy is a useful tool to specify a group of prognostically unfavourable patients.
Endometrial cancer
DNA ploidy
Molecular immunomarkers
Prognostic factors
Back to top